Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2019 09:00 ET | Source: Druggability Technologies Holdings Ltd

DRGT Completes a Pivotal Phase I Trial; Results Confirm 6X Faster Attainment Of Maximum Plasma Levels For Pain Management Compared To Currently Available COX-2 Inhibitor

BUDAPEST, Hungary, June 10, 2019 (GLOBE NEWSWIRE) -- Druggability Technologies Holdings (DRGT) today announced results from a pharmacokinetic study of their novel formulation of celecoxib...